Endovastec(SH:688016) Sou Hu Cai Jing·2025-08-25 15:52Group 1 - The core viewpoint of the news is that Xinmai Medical (688016) has experienced a decline in stock price and financial performance, indicating potential challenges ahead for the company [1][3] - As of August 25, 2025, Xinmai Medical's stock closed at 119.19 yuan, down 1.58%, with a turnover rate of 3.49% and a trading volume of 43,000 hands, amounting to a transaction value of 511 million yuan [1] - The net outflow of main funds today was 52.23 million yuan, accounting for 10.21% of the transaction amount, with significant outflows from large orders [1] Group 2 - For the first quarter of 2025, Xinmai Medical reported total operating revenue of 332 million yuan, a year-on-year decrease of 7.23%, and a net profit attributable to shareholders of 130 million yuan, down 29.66% year-on-year [1] - The company's current ratio is 6.284, quick ratio is 5.773, and debt-to-asset ratio is 13.00%, indicating a strong liquidity position [1] - Xinmai Medical, established in 2012 and based in Shanghai, has a registered capital of 1.23 billion yuan and has made investments in five companies, participated in 355 bidding projects, and holds 41 trademarks and 202 patents [2]